Can a morning light session boost immunotherapy? small trial aims to find out
NCT ID NCT07661966
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether using bright light therapy for an hour each morning, delivered through an iPad app, is tolerable for people with advanced melanoma or non-small cell lung cancer who are about to start immunotherapy. The idea is that synchronizing the body's internal clock might help the immune therapy work better. Only 12 participants will be enrolled, and the main goal is to see if they can stick with the light therapy routine, not yet to measure cancer outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bright light therapy delivered via Circadian OS iPad application
What this could lead to
If this works, it could show that bright light therapy is a tolerable way to help align patients' body clocks, potentially improving how well immunotherapy works.
What could go wrong
This is a very small pilot study with only 12 people, focused on whether the therapy is tolerable, not on whether it actually improves cancer outcomes. It may not lead to any clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine
New York, New York, 10021, United States
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact